Melanoma Trial, Recruiting NCT06206707 Sponsor: University of Aarhus Condition: Melanoma
Back to Melanoma

Melanoma Trial, Recruiting

NCT06206707
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older.
  • You have been diagnosed with malignant melanoma (skin cancer) and/or kidney cancer, confirmed by a tissue sample test.
  • You have received a specific type of cancer immunotherapy drug (such as Nivolumab, Pembrolizumab, Cemiplimab, Atezolizumab, Durvalumab, Avelumab, or Ipilimumab), either alone or in combination, within the last 8 weeks.
  • You are experiencing moderate to severe diarrhea (at least a certain number of loose or watery stools per day) as a side effect of your immunotherapy treatment.
  • A stool test has come back negative for infections, including a bacteria called C. difficile, after your diarrhea started.
  • You are willing and able to sign a consent form to take part in the trial.

Who may not be able to join:

  • You currently have a bacterial infection that requires antibiotic treatment.
  • You are pregnant or breastfeeding (a urine pregnancy test may be required to confirm this for some people).
  • You had a pre-existing bowel condition causing diarrhea before starting immunotherapy, such as inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis).
  • You are unable to swallow capsules.
  • You are unable to understand written or spoken information about the trial (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 5 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Christian L Hvas, PhD, University of Aarhus

Phone: +4540408207

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
23 January 2024
Est. completion
30 June 2026

Where this trial is recruiting

🇩🇰 Denmark

Primary endpoints

Clinical remission of immune-mediated diarrhea

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov